IP Library Granted Patent US 11,241,407
Granted Patent B2
US 11,241,407 · App. 16/897,152 · Granted Feb 8, 2022

Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy

Inventors: Xiyan Li (Mountain View, CA); Xin Wang (Palo Alto, CA); Xiaolu Yang (Menlo Park, CA)
Assignee: Filtricine, Inc.
A61K31/198A61K31/07A61K31/14A61K31/355A61K31/375A61K31/4188A61K31/455A61K31/51A61K31/519A61K31/525A61K31/593A61K31/675A61K31/7004A61K31/714A61K33/04A61K33/16A61K33/18A61K33/24A61K33/26A61K33/30A61K33/32A61K33/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,407
App. No.
16/897,152
Granted
Feb 8, 2022
Kind
B2
Abstract

The present disclosure provides compositions and methods for treating cancer with nutritionally modified diets and/or dialysis treatment, such as through amino acid depletion of one or more nonessential amino acids. In some aspects, the present disclosure provides compositions and methods for treating obesity with such modified diets and/or dialysis treatment. Furthermore, in some aspects, the present disclosure provides compositions and methods for treating renal disease with such modified diets and/or dialysis treatment.

Claims (43)

1. A liquid composition comprising:

(a) dextrose at an amount of at least 1.0% w/v;

(b) at least one vitamin selected from a group consisting of vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, and choline;

(c) at least one ion selected from a group consisting of sodium, calcium, magnesium, chloride, and lactate;

(d) at least one essential amino acid selected from a group consisting of histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, and arginine; and

(e) an aqueous solution,

wherein the liquid composition is characterized in that

(i) it is substantially free of cysteine and/or cystine,

(ii) it has a molar ratio of cysteine to essential amino acid(s) less than 0.1;

(iii) it has a pH of 4.0-6.5, and

(iv) it has an osmolarity of 300-720 milliosmolar (mOsmol/L), and

wherein the liquid composition is substantially free of nonessential amino acids selected from alanine, asparagine, aspartate, cysteine, glycine, proline, glutamine, serine, and tyrosine.

2. The liquid composition of claim 1 , wherein the liquid composition comprises methionine or arginine.

3. The liquid composition of claim 1 , wherein each of said at least one vitamin is present at an amount of at least 0.000010 μM.

4. The liquid composition of claim 1 , wherein the at least one vitamin comprises vitamin C or vitamin B.

5. The liquid composition of claim 1 , wherein the liquid composition comprises vitamin B at an amount of at least 0.00005 μM.

6. The liquid composition of claim 1 , wherein the liquid composition comprises glutamate.

7. The liquid composition of claim 6 , wherein said glutamate is present at an amount of at least 1 μM.

8. The liquid composition of claim 6 , wherein the liquid composition is free of nonessential amino acids other than glutamate.

9. The liquid composition of claim 1 , wherein each of said at least one ion is present at an amount of at least 0.1 milliequivalents per liter (mEq/L).

10. The liquid composition of claim 1 , further comprising at least one nonessential amino acid.

11. The liquid composition of claim 1 , wherein the liquid composition is a dialysis solution.

12. The liquid composition of claim 1 , comprising essential amino acids including histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine, wherein each of said at least one essential amino acid is present at an amount of at least 10 μM.

13. The liquid composition of claim 1 , wherein the composition is configured for reducing or depleting cysteine and/or cystine from a subject to whom the composition is administered.

14. A dry composition comprising:

(a) dextrose at an amount of at least 0.1 grams;

(b) at least one vitamin selected from a group consisting of vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, and choline;

(c) at least one ion selected from a group consisting of sodium, calcium, magnesium, chloride, and lactate; and -3-

(d) at least one essential amino acid selected from a group consisting of histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, and arginine,

wherein the dry composition (i) is substantially free of cysteine and/or cystine and (ii) has a molar ratio of cysteine to essential amino acids less than 0.1, and

wherein the dry composition is substantially free of nonessential amino acids selected from alanine, asparagine, aspartate, cysteine, glycine, proline, glutamine, serine, and tyrosine.

15. The dry composition of claim 14 , wherein said dry composition comprises methionine or arginine.

16. The dry composition of claim 14 , wherein said at least one vitamin is present at an amount of at least 0.01 μg.

17. The dry composition of claim 14 , wherein the at least one vitamin comprises vitamin C or vitamin B.

18. The dry composition of claim 14 , wherein the dry composition comprises glutamate.

19. The dry composition of claim 18 , wherein said glutamate is present at an amount of at least 0.1 mg.

20. The dry composition of claim 14 , further comprising at least one nonessential amino acid.

21. The dry composition of claim 18 , wherein the dry composition is free of nonessential amino acids other than glutamate.

22. The dry composition of claim 14 , wherein the dry composition is a dialysis mixture.

23. A concentrated composition comprising a dry composition of claim 14 , and an initial aqueous solution, wherein the dry composition is dissolved in the initial aqueous solution.

24. The dry composition of claim 14 , comprising essential amino acids including histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine, wherein each of said at least one essential amino acid is present at an amount of at least 2 μg.

25. The dry composition of claim 14 , wherein the composition is configured for reducing or depleting cysteine and/or cystine from a subject to whom the composition is administered.

26. The dry composition of claim 14 , wherein the composition is stored in a container.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2020
From: LI, XIYAN; WANG, XIN; YANG, XIAOLU
To: FILTRICINE, INC.
Reel/Frame 053183/0547 →
Continuity (3)
Continuation PCTUS2018065045 · Dec 11, 2018
Provisional Application 62597392 · Dec 11, 2017
Related Publication 20200297679A1 · Sep 24, 2020
Cited By (3)
US 12,220,402 US 12,324,807 US 12,478,601